Kiniksa Pharmaceuticals Key Executives
This section highlights Kiniksa Pharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at Kiniksa Pharmaceuticals
(Showing 0 of )
Kiniksa Pharmaceuticals Earnings
This section highlights Kiniksa Pharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-25 | $-0.06 | $-0.12 |
| Read Transcript | Q3 | 2024 | 2024-10-29 | $-0.02 | $-0.18 |
| Read Transcript | Q2 | 2024 | 2024-07-23 | $-0.09 | $-0.06 |
| Read Transcript | Q1 | 2024 | 2024-04-23 | $-0.14 | $-0.25 |
| Read Transcript | Q4 | 2023 | 2024-02-28 | $-0.11 | $0.04 |
| Read Transcript | Q3 | 2023 | 2023-10-31 | $-0.18 | $-0.20 |
| Read Transcript | Q2 | 2023 | 2023-07-25 | $-0.16 | $-0.02 |
| Read Transcript | Q1 | 2023 | 2023-05-06 | N/A | N/A |
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
$23.41
Stock Price
$1.70B
Market Cap
200.00K
Employees
Hamilton, None
Location
Financial Statements
Access annual & quarterly financial statements for Kiniksa Pharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $423.24M | $270.26M | $220.18M | $38.54M | $- |
| Cost of Revenue | $- | $56.52M | $46.97M | $9.10M | $3.81M |
| Gross Profit | $423.24M | $213.74M | $173.21M | $29.44M | $-3.81M |
| Gross Profit Ratio | 100.00% | 79.10% | 78.67% | 76.40% | 0.00% |
| Research and Development Expenses | $111.62M | $76.10M | $65.49M | $99.30M | $112.04M |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $168.01M | $129.43M | $97.95M | $85.95M | $45.32M |
| Other Expenses | $189.22M | $33.41M | $1.25M | $835.00K | $- |
| Operating Expenses | $468.86M | $238.93M | $163.44M | $186.08M | $157.36M |
| Cost and Expenses | $468.86M | $295.45M | $210.41M | $195.18M | $157.36M |
| Interest Income | $- | $8.54M | $1.25M | $97.00K | $1.13M |
| Interest Expense | $- | $- | $1.25M | $- | $- |
| Depreciation and Amortization | $- | $2.34M | $4.22M | $4.09M | $3.81M |
| EBITDA | $-45.62M | $-22.86M | $9.77M | $-154.28M | $-152.42M |
| EBITDA Ratio | -10.78% | -8.46% | 4.44% | -406.38% | 0.00% |
| Operating Income | $-45.62M | $-25.20M | $7.37M | $-156.64M | $-157.36M |
| Operating Income Ratio | -10.78% | -9.32% | 3.35% | -406.38% | 0.00% |
| Total Other Income Expenses Net | $9.46M | $8.54M | $1.25M | $97.00K | $1.13M |
| Income Before Tax | $-36.15M | $-16.65M | $11.03M | $-156.54M | $-156.23M |
| Income Before Tax Ratio | -8.54% | -6.16% | 5.01% | -406.13% | 0.00% |
| Income Tax Expense | $7.04M | $-30.74M | $-172.34M | $1.39M | $5.15M |
| Net Income | $-43.19M | $14.08M | $183.36M | $-157.92M | $-161.38M |
| Net Income Ratio | -10.21% | 5.21% | 83.28% | -409.72% | 0.00% |
| EPS | $-0.60 | $0.20 | $2.64 | $-2.30 | $-2.61 |
| EPS Diluted | $-0.60 | $0.20 | $2.60 | $-2.30 | $-2.61 |
| Weighted Average Shares Outstanding | 71.42M | 70.06M | 69.38M | 68.58M | 61.84M |
| Weighted Average Shares Outstanding Diluted | 71.42M | 71.92M | 70.42M | 68.58M | 61.84M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $122.54M | $112.21M | $108.63M | $79.86M | $83.39M | $67.05M | $71.47M | $48.34M | $61.88M | $99.14M | $26.97M | $32.19M | $18.75M | $12.10M | $7.70M | $- | $- | $- | $- | $- |
| Cost of Revenue | $-62.23M | $49.42M | $42.45M | $31.54M | $26.76M | $26.40M | $21.68M | $7.04M | $14.23M | $11.56M | $5.03M | $4.22M | $3.87M | $2.77M | $2.47M | $883.00K | $- | $- | $- | $- |
| Gross Profit | $184.76M | $62.80M | $66.18M | $48.32M | $56.64M | $40.65M | $49.79M | $41.31M | $47.65M | $87.58M | $21.94M | $27.97M | $14.88M | $9.33M | $5.24M | $-883.00K | $- | $- | $- | $- |
| Gross Profit Ratio | 150.78% | 56.00% | 60.90% | 60.50% | 67.90% | 60.60% | 69.70% | 85.40% | 77.00% | 88.30% | 81.40% | 86.90% | 79.40% | 77.10% | 68.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $35.22M | $26.06M | $23.90M | $26.18M | $19.82M | $17.11M | $23.77M | $15.17M | $14.39M | $16.48M | $13.80M | $20.82M | $27.43M | $19.24M | $23.95M | $28.68M | $37.40M | $31.42M | $22.32M | $20.90M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $15.50M | $11.80M | $9.54M | $8.49M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.40M | $- | $-600.00K | $-800.00K |
| Selling General and Administrative Expenses | $40.53M | $46.40M | $42.40M | $38.68M | $36.74M | $34.47M | $29.18M | $29.05M | $27.21M | $24.68M | $23.84M | $22.22M | $22.74M | $20.76M | $21.85M | $20.60M | $15.50M | $11.80M | $9.54M | $8.49M |
| Other Expenses | $128.31M | $- | $2.42M | $2.27M | $2.37M | $2.43M | $1.92M | $8.29M | $794.00K | $6.94M | $3.67M | $8.25M | $835.00K | $2.77M | $2.47M | $- | $- | $- | $- | $- |
| Operating Expenses | $204.06M | $72.46M | $66.29M | $64.86M | $56.55M | $51.57M | $52.94M | $52.51M | $41.60M | $41.16M | $41.31M | $51.29M | $51.01M | $39.99M | $45.79M | $49.28M | $52.90M | $43.22M | $31.86M | $29.39M |
| Cost and Expenses | $141.84M | $121.87M | $108.75M | $96.40M | $83.31M | $77.97M | $74.63M | $59.54M | $55.84M | $52.72M | $46.34M | $55.51M | $54.88M | $42.76M | $48.26M | $49.28M | $52.90M | $43.22M | $31.86M | $29.39M |
| Interest Income | $- | $- | $- | $- | $2.37M | $2.43M | $1.92M | $1.83M | $794.00K | $322.00K | $103.00K | $34.00K | $77.00K | $5.00K | $6.00K | $9.00K | $30.00K | $49.00K | $266.00K | $789.00K |
| Interest Expense | $- | $- | $- | $- | $1.83M | $- | $- | $- | $794.00K | $322.00K | $103.00K | $34.00K | $77.00K | $5.00K | $6.00K | $9.00K | $30.00K | $49.00K | $266.00K | $789.00K |
| Depreciation and Amortization | $400.00K | $399.00K | $430.00K | $466.00K | $236.00K | $999.00K | $1.06M | $1.13M | $1.08M | $949.00K | $1.10M | $1.09M | $1.11M | $1.07M | $1.02M | $883.00K | $567.00K | $649.00K | $595.00K | $594.00K |
| EBITDA | $-18.90M | $-9.66M | $313.00K | $-16.08M | $317.00K | $-10.32M | $-2.55M | $-10.60M | $7.92M | $46.41M | $-18.72M | $-22.66M | $-35.46M | $-30.01M | $-39.84M | $-48.97M | $-52.33M | $-42.57M | $-31.27M | $-28.79M |
| EBITDA Ratio | -15.42% | -8.61% | 0.29% | -20.13% | 0.38% | -16.30% | -4.41% | -23.16% | 9.77% | 46.82% | -71.81% | -72.44% | -192.75% | -253.55% | -526.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-19.30M | $-9.66M | $-117.00K | $-16.54M | $81.00K | $-10.93M | $-3.15M | $-11.20M | $6.05M | $46.41M | $-19.37M | $-23.25M | $-36.13M | $-30.67M | $-40.55M | $-49.28M | $-52.90M | $-43.22M | $-31.86M | $-29.39M |
| Operating Income Ratio | -15.75% | -8.61% | -0.11% | -20.71% | 0.10% | -16.30% | -4.41% | -23.16% | 9.77% | 46.82% | -71.81% | -72.23% | -192.75% | -253.55% | -526.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $2.32M | $2.46M | $2.42M | $2.27M | $2.37M | $2.43M | $1.92M | $1.83M | $794.00K | $322.00K | $103.00K | $34.00K | $77.00K | $5.00K | $6.00K | $9.00K | $30.00K | $49.00K | $266.00K | $789.00K |
| Income Before Tax | $-16.98M | $-7.20M | $2.30M | $-14.28M | $2.45M | $-8.50M | $-1.24M | $-9.36M | $6.84M | $46.73M | $-19.27M | $-23.29M | $-36.05M | $-30.66M | $-40.55M | $-49.27M | $-52.87M | $-43.17M | $-31.59M | $-28.60M |
| Income Before Tax Ratio | -13.86% | -6.42% | 2.12% | -17.88% | 2.94% | -12.68% | -1.73% | -19.37% | 11.05% | 47.14% | -71.43% | -72.34% | -192.34% | -253.51% | -526.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $-8.09M | $5.49M | $6.21M | $3.43M | $-22.79M | $5.36M | $-16.21M | $2.91M | $2.38M | $-177.36M | $716.00K | $1.93M | $279.00K | $-118.00K | $1.01M | $210.00K | $789.00K | $667.00K | $5.88M | $-2.18M |
| Net Income | $-8.89M | $-12.69M | $-3.91M | $-17.70M | $25.24M | $-13.86M | $14.97M | $-12.27M | $4.46M | $224.09M | $-19.98M | $-25.21M | $-36.33M | $-30.54M | $-41.56M | $-49.48M | $-53.66M | $-43.84M | $-37.47M | $-26.42M |
| Net Income Ratio | -7.25% | -11.31% | -3.60% | -22.17% | 30.26% | -20.66% | 20.95% | -25.38% | 7.21% | 226.05% | -74.08% | -78.32% | -193.83% | -252.53% | -539.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.12 | $-0.18 | $-0.06 | $-0.25 | $0.36 | $-0.20 | $0.21 | $-0.18 | $0.06 | $3.23 | $-0.29 | $-0.36 | $-0.53 | $-0.44 | $-0.61 | $-0.72 | $-0.79 | $-0.66 | $-0.65 | $-0.48 |
| EPS Diluted | $-0.12 | $-0.18 | $-0.06 | $-0.25 | $0.35 | $-0.20 | $0.21 | $-0.18 | $0.06 | $3.18 | $-0.29 | $-0.36 | $-0.53 | $-0.44 | $-0.61 | $-0.72 | $-0.79 | $-0.66 | $-0.65 | $-0.48 |
| Weighted Average Shares Outstanding | 71.42M | 71.73M | 71.00M | 70.63M | 70.37M | 70.19M | 69.92M | 69.75M | 69.61M | 69.45M | 68.90M | 69.14M | 68.97M | 68.66M | 68.14M | 68.27M | 68.06M | 65.96M | 57.91M | 55.32M |
| Weighted Average Shares Outstanding Diluted | 71.42M | 71.73M | 71.00M | 70.63M | 72.66M | 70.19M | 71.63M | 69.75M | 71.37M | 70.55M | 69.29M | 69.14M | 68.97M | 68.66M | 68.40M | 68.27M | 68.06M | 65.96M | 57.91M | 55.32M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $183.58M | $107.95M | $122.72M | $122.47M | $114.04M |
| Short Term Investments | $60.05M | $98.42M | $67.89M | $59.73M | $209.44M |
| Cash and Short Term Investments | $243.63M | $206.37M | $190.61M | $182.20M | $323.48M |
| Net Receivables | $41.72M | $21.27M | $20.32M | $3.98M | $- |
| Inventory | $26.36M | $31.12M | $21.60M | $3.67M | $- |
| Other Current Assets | $20.08M | $17.54M | $10.54M | $13.17M | $9.77M |
| Total Current Assets | $331.80M | $276.30M | $243.06M | $196.45M | $333.25M |
| Property Plant Equipment Net | $11.04M | $12.66M | $7.04M | $8.38M | $10.62M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $16.25M | $17.25M | $18.25M | $19.25M | $- |
| Goodwill and Intangible Assets | $16.25M | $17.25M | $18.25M | $19.25M | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $211.15M | $219.28M | $185.50M | $- | $10.00K |
| Other Non-Current Assets | $10.31M | $827.00K | $5.82M | $8.72M | $5.59M |
| Total Non-Current Assets | $248.75M | $250.03M | $216.61M | $36.35M | $16.21M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $580.55M | $526.32M | $459.67M | $232.80M | $349.46M |
| Account Payables | $2.04M | $8.25M | $7.90M | $1.87M | $503.00K |
| Short Term Debt | $3.99M | $2.25M | $6.60M | $6.76M | $4.21M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $31.81M | $307.00K | $12.00M | $38.03M | $29.20M |
| Other Current Liabilities | $62.78M | $52.86M | $32.56M | $36.19M | $27.13M |
| Total Current Liabilities | $100.62M | $63.67M | $47.07M | $44.82M | $31.85M |
| Long Term Debt | $7.86M | $10.01M | $2.62M | $2.67M | $4.88M |
| Deferred Revenue Non-Current | $- | $11.95M | $12.00M | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $33.63M | $1.86M | $1.84M | $270.00K | $805.00K |
| Total Non-Current Liabilities | $41.50M | $23.82M | $16.46M | $2.94M | $5.68M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $142.12M | $87.48M | $63.52M | $47.76M | $37.53M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $20.00K | $20.00K | $19.00K | $18.00K | $18.00K |
| Retained Earnings | $-521.14M | $-477.95M | $-492.03M | $-675.40M | $-517.47M |
| Accumulated Other Comprehensive Income Loss | $-163.00K | $6.00K | $44.00K | $-66.00K | $-34.00K |
| Other Total Stockholders Equity | $959.72M | $916.76M | $888.12M | $860.48M | $829.42M |
| Total Stockholders Equity | $438.44M | $438.84M | $-492.03M | $-675.40M | $-517.47M |
| Total Equity | $438.44M | $438.84M | $-492.03M | $-675.40M | $-517.47M |
| Total Liabilities and Stockholders Equity | $580.55M | $526.32M | $-428.51M | $-627.63M | $-479.94M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $580.55M | $526.32M | $-428.51M | $-627.63M | $-479.94M |
| Total Investments | $60.05M | $98.42M | $67.89M | $59.73M | $209.44M |
| Total Debt | $9.86M | $12.26M | $5.92M | $6.05M | $6.99M |
| Net Debt | $-173.73M | $-95.70M | $-116.80M | $-116.42M | $-107.05M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $183.58M | $97.38M | $99.27M | $141.08M | $107.95M | $117.83M | $112.57M | $80.62M | $122.72M | $175.76M | $94.31M | $63.32M | $122.47M | $190.18M | $167.95M | $119.86M | $114.04M | $85.87M | $123.46M | $106.34M |
| Short Term Investments | $60.05M | $126.40M | $119.49M | $72.47M | $98.42M | $83.26M | $72.42M | $106.88M | $67.89M | $24.96M | $43.90M | $82.25M | $59.73M | $10.00M | $57.91M | $144.17M | $209.44M | $278.52M | $128.94M | $97.87M |
| Cash and Short Term Investments | $243.63M | $223.78M | $218.76M | $213.55M | $206.37M | $201.08M | $184.99M | $187.49M | $190.61M | $200.72M | $138.21M | $145.58M | $182.20M | $200.18M | $225.87M | $264.02M | $323.48M | $364.39M | $252.40M | $204.21M |
| Net Receivables | $41.72M | $24.89M | $20.45M | $15.99M | $21.27M | $3.04M | $24.65M | $7.42M | $20.32M | $11.16M | $7.81M | $29.44M | $3.98M | $3.22M | $2.55M | $- | $- | $- | $- | $- |
| Inventory | $26.36M | $28.68M | $34.86M | $27.28M | $31.12M | $25.58M | $23.96M | $23.43M | $21.60M | $14.62M | $19.92M | $13.22M | $3.67M | $5.61M | $6.38M | $2.19M | $- | $- | $- | $- |
| Other Current Assets | $20.08M | $33.95M | $26.95M | $13.77M | $17.54M | $26.40M | $12.44M | $13.16M | $10.54M | $30.62M | $28.01M | $21.03M | $13.17M | $17.00M | $10.01M | $9.35M | $9.77M | $28.04M | $24.19M | $17.70M |
| Total Current Assets | $331.80M | $311.30M | $301.02M | $270.59M | $276.30M | $256.11M | $184.99M | $231.50M | $243.06M | $241.81M | $179.94M | $198.76M | $196.45M | $217.51M | $244.81M | $275.56M | $333.25M | $378.41M | $264.49M | $213.06M |
| Property Plant Equipment Net | $11.04M | $11.66M | $12.40M | $13.04M | $12.66M | $13.59M | $14.33M | $1.39M | $7.04M | $8.17M | $6.22M | $7.29M | $8.38M | $9.30M | $8.84M | $9.80M | $10.62M | $5.74M | $6.53M | $7.43M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $16.25M | $16.50M | $16.75M | $17.00M | $17.25M | $17.50M | $17.75M | $18.00M | $18.25M | $18.50M | $18.75M | $19.00M | $19.25M | $19.50M | $19.75M | $20.00M | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $16.25M | $16.50M | $16.75M | $17.00M | $17.25M | $17.50M | $17.75M | $18.00M | $18.25M | $18.50M | $18.75M | $19.00M | $19.25M | $19.50M | $19.75M | $20.00M | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $-1 | $-244.95M | $-1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $211.15M | $207.99M | $204.35M | $214.92M | $219.28M | $193.57M | $203.86M | $184.42M | $185.50M | $185.84M | $- | $- | $- | $- | $- | $- | $10.00K | $3.00K | $- | $5.41M |
| Other Non-Current Assets | $10.31M | $7.85M | $7.90M | $249.08M | $827.00K | $2.29M | $2.35M | $7.55M | $5.82M | $5.63M | $5.67M | $5.92M | $8.72M | $6.55M | $5.81M | $5.80M | $5.59M | $258.00K | $415.00K | $210.00K |
| Total Non-Current Assets | $248.75M | $244.00M | $241.41M | $249.08M | $250.02M | $226.95M | $238.29M | $211.36M | $216.61M | $218.14M | $30.64M | $32.21M | $36.35M | $35.35M | $34.40M | $35.59M | $16.21M | $6.00M | $6.95M | $13.05M |
| Other Assets | $- | $- | $1 | $- | $1 | $- | $61.05M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $580.55M | $555.30M | $542.43M | $519.67M | $526.32M | $483.06M | $484.33M | $442.86M | $459.67M | $459.95M | $210.58M | $230.97M | $232.80M | $252.86M | $279.21M | $311.16M | $349.46M | $384.41M | $271.44M | $226.11M |
| Account Payables | $2.04M | $8.33M | $7.39M | $5.63M | $8.25M | $1.01M | $648.00K | $1.39M | $7.90M | $1.47M | $2.52M | $3.38M | $1.87M | $1.65M | $4.16M | $2.76M | $503.00K | $3.92M | $2.37M | $4.27M |
| Short Term Debt | $1.99M | $4.06M | $4.17M | $4.56M | $4.51M | $4.63M | $4.48M | $6.96M | $3.30M | $6.55M | $6.67M | $6.62M | $3.38M | $6.49M | $5.27M | $4.75M | $2.11M | $2.98M | $3.36M | $3.38M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $12.00K | $156.00K | $307.00K | $2.56M | $4.67M | $6.50M | $12.00M | $12.09M | $12.00M | $12.00M | $38.03M | $28.53M | $31.06M | $- | $29.20M | $- | $- | $- |
| Other Current Liabilities | $96.59M | $83.56M | $72.72M | $53.87M | $50.61M | $45.27M | $37.67M | $21.74M | $35.87M | $36.38M | $34.35M | $40.35M | $39.58M | $26.29M | $29.35M | $27.94M | $29.24M | $17.98M | $14.82M | $11.69M |
| Total Current Liabilities | $100.62M | $95.95M | $84.29M | $64.21M | $63.67M | $53.47M | $47.47M | $36.59M | $47.07M | $56.49M | $43.54M | $50.35M | $44.82M | $34.43M | $38.78M | $35.45M | $31.85M | $24.89M | $20.55M | $19.34M |
| Long Term Debt | $7.86M | $8.56M | $9.32M | $9.86M | $10.01M | $10.65M | $11.28M | $2.13M | $2.62M | $3.44M | $1.28M | $2.10M | $2.67M | $3.50M | $3.50M | $4.20M | $4.88M | $55.00K | $139.00K | $551.00K |
| Deferred Revenue Non-Current | $31.81M | $11.81M | $11.80M | $11.81M | $11.95M | $11.87M | $12.01M | $12.16M | $12.00M | $14.20M | $12.00M | $12.00M | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1.82M | $1.96M | $1.93M | $1.89M | $1.86M | $1.95M | $1.92M | $1.88M | $1.84M | $1.82M | $260.00K | $271.00K | $270.00K | $885.00K | $1.14M | $809.00K | $805.00K | $957.00K | $334.00K | $381.00K |
| Total Non-Current Liabilities | $41.50M | $22.34M | $23.04M | $23.57M | $23.82M | $24.47M | $25.20M | $16.18M | $16.46M | $19.45M | $13.54M | $14.37M | $2.94M | $4.38M | $4.64M | $5.01M | $5.68M | $1.01M | $473.00K | $932.00K |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $142.12M | $118.29M | $107.33M | $87.78M | $87.48M | $77.94M | $72.68M | $52.77M | $63.52M | $75.94M | $57.08M | $64.72M | $47.76M | $38.81M | $43.42M | $40.46M | $37.53M | $25.90M | $21.02M | $20.27M |
| Preferred Stock | $- | $- | $110.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $20.00K | $20.00K | $20.00K | $20.00K | $20.00K | $15.00K | $14.00K | $14.00K | $19.00K | $19.00K | $19.00K | $19.00K | $18.00K | $18.00K | $18.00K | $18.00K | $18.00K | $18.00K | $16.00K | $15.00K |
| Retained Earnings | $-521.14M | $-512.25M | $-499.56M | $-495.65M | $-477.95M | $-503.19M | $-489.33M | $-504.30M | $-492.03M | $-496.50M | $-720.59M | $-700.61M | $-675.40M | $-639.06M | $-608.52M | $-566.96M | $-517.47M | $-463.82M | $-419.98M | $-382.51M |
| Accumulated Other Comprehensive Income Loss | $-163.00K | $-41.00K | $-130.00K | $-53.00K | $6.00K | $-1.00K | $13.00K | $55.00K | $44.00K | $-70.00K | $-90.00K | $-103.00K | $-66.00K | $-45.00K | $27.00K | $-21.00K | $-34.00K | $6.00K | $9.00K | $240.00K |
| Other Total Stockholders Equity | $959.72M | $949.28M | $934.77M | $927.58M | $916.76M | $908.29M | $900.96M | $894.33M | $888.12M | $880.55M | $874.15M | $866.93M | $860.48M | $853.14M | $844.26M | $837.66M | $829.42M | $822.30M | $670.37M | $588.09M |
| Total Stockholders Equity | $438.44M | $437.01M | $435.10M | $431.89M | $438.84M | $-503.19M | $-489.33M | $-504.30M | $-492.03M | $-496.50M | $-720.59M | $-700.61M | $185.04M | $214.05M | $235.78M | $270.70M | $311.94M | $358.51M | $250.42M | $205.83M |
| Total Equity | $438.44M | $437.01M | $435.10M | $431.89M | $438.84M | $-503.19M | $-489.33M | $-504.30M | $-492.03M | $-496.50M | $-720.59M | $-700.61M | $185.04M | $214.05M | $235.78M | $270.70M | $311.94M | $358.51M | $250.42M | $205.83M |
| Total Liabilities and Stockholders Equity | $580.55M | $555.30M | $542.43M | $519.67M | $526.32M | $-425.25M | $-416.66M | $-451.54M | $-428.51M | $-420.55M | $-663.51M | $-635.89M | $232.80M | $252.86M | $279.21M | $311.16M | $349.46M | $384.41M | $271.44M | $226.11M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $580.55M | $555.30M | $542.43M | $519.67M | $526.32M | $-425.25M | $-416.66M | $-451.54M | $-428.51M | $-420.55M | $-663.51M | $-635.89M | $232.80M | $252.86M | $279.21M | $311.16M | $349.46M | $384.41M | $271.44M | $226.11M |
| Total Investments | $60.05M | $126.40M | $119.49M | $72.47M | $98.42M | $83.26M | $72.42M | $106.88M | $67.89M | $24.96M | $43.90M | $82.25M | $59.73M | $10.00M | $57.91M | $144.17M | $209.44M | $278.52M | $128.94M | $97.87M |
| Total Debt | $9.86M | $10.60M | $11.40M | $12.14M | $12.26M | $12.96M | $13.52M | $5.62M | $5.92M | $6.71M | $4.61M | $5.41M | $6.05M | $6.75M | $6.14M | $6.57M | $6.99M | $1.55M | $1.82M | $2.24M |
| Net Debt | $-173.73M | $-86.78M | $-87.87M | $-128.94M | $-95.70M | $-104.86M | $-99.05M | $-75.00M | $-116.80M | $-169.05M | $-89.69M | $-57.92M | $-116.42M | $-183.44M | $-161.82M | $-113.28M | $-107.05M | $-84.33M | $-121.64M | $-104.10M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-43.19M | $14.08M | $183.36M | $-157.92M | $-161.38M |
| Depreciation and Amortization | $1.70M | $2.34M | $2.40M | $2.35M | $2.40M |
| Deferred Income Tax | $8.13M | $-33.79M | $-185.50M | $11.00K | $4.36M |
| Stock Based Compensation | $30.69M | $27.15M | $25.12M | $25.17M | $20.88M |
| Change in Working Capital | $24.81M | $1.35M | $-22.57M | $689.00K | $-4.32M |
| Accounts Receivables | $-20.46M | $-950.00K | $-8.68M | $-3.91M | $- |
| Inventory | $4.76M | $-9.52M | $-17.92M | $-3.67M | $- |
| Accounts Payables | $-6.31M | $347.00K | $6.03M | $1.37M | $-4.97M |
| Other Working Capital | $46.81M | $11.48M | $-2.01M | $6.91M | $654.00K |
| Other Non Cash Items | $3.55M | $2.17M | $2.99M | $3.40M | $1.52M |
| Net Cash Provided by Operating Activities | $25.69M | $13.30M | $5.81M | $-126.30M | $-136.53M |
| Investments in Property Plant and Equipment | $-277.00K | $-130.00K | $-105.00K | $-20.41M | $-283.00K |
| Acquisitions Net | $- | $- | $91.00K | $20.00M | $23.16M |
| Purchases of Investments | $-202.01M | $-204.93M | $-135.86M | $-157.25M | $-430.21M |
| Sales Maturities of Investments | $239.94M | $175.51M | $127.80M | $306.30M | $407.05M |
| Other Investing Activities | $25.00K | $- | $-7.97M | $-20.00M | $-23.16M |
| Net Cash Used for Investing Activities | $37.67M | $-29.56M | $-8.08M | $128.63M | $-23.44M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $3.42M | $5.88M | $228.22M |
| Common Stock Repurchased | $-4.98M | $-2.21M | $-901.00K | $5.88M | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $17.25M | $3.70M | $3.42M | $5.88M | $-1.14M |
| Net Cash Used Provided by Financing Activities | $12.27M | $1.50M | $2.52M | $5.88M | $227.09M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $75.63M | $-14.76M | $245.00K | $8.22M | $67.11M |
| Cash at End of Period | $183.58M | $107.95M | $122.72M | $122.47M | $114.25M |
| Cash at Beginning of Period | $107.95M | $122.72M | $122.47M | $114.25M | $47.14M |
| Operating Cash Flow | $25.69M | $13.30M | $5.81M | $-126.30M | $-136.53M |
| Capital Expenditure | $-277.00K | $-130.00K | $-105.00K | $-20.41M | $-283.00K |
| Free Cash Flow | $25.41M | $13.17M | $5.70M | $-146.71M | $-136.81M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-8.89M | $-12.69M | $-3.91M | $-17.70M | $25.24M | $-13.86M | $14.97M | $-12.27M | $4.46M | $224.09M | $-19.98M | $-25.21M | $-36.33M | $-30.54M | $-41.56M | $-49.48M | $-53.66M | $-43.84M | $-37.47M | $-26.42M |
| Depreciation and Amortization | $400.00K | $399.00K | $430.00K | $466.00K | $236.00K | $603.00K | $602.00K | $596.00K | $602.00K | $493.00K | $651.00K | $656.00K | $668.00K | $658.00K | $717.00K | $312.00K | $567.00K | $649.00K | $595.00K | $594.00K |
| Deferred Income Tax | $-3.16M | $-3.64M | $10.57M | $4.37M | $-25.71M | $10.29M | $-19.44M | $1.08M | $348.00K | $-185.84M | $- | $- | $11.00K | $14.00K | $-10.00K | $10.00K | $40.00K | $-51.00K | $5.41M | $-1.04M |
| Stock Based Compensation | $8.30M | $7.83M | $7.36M | $7.21M | $7.77M | $6.79M | $6.47M | $6.12M | $6.37M | $6.04M | $6.68M | $6.03M | $6.13M | $6.20M | $5.72M | $7.13M | $6.26M | $5.56M | $4.85M | $4.21M |
| Change in Working Capital | $20.54M | $5.60M | $-9.91M | $8.58M | $-3.96M | $11.01M | $-5.96M | $260.00K | $-23.95M | $16.63M | $3.97M | $-19.22M | $9.75M | $-5.54M | $-4.44M | $911.00K | $4.60M | $3.13M | $-2.83M | $-9.21M |
| Accounts Receivables | $-16.84M | $-4.44M | $-4.46M | $5.27M | $-18.23M | $21.61M | $-17.23M | $5.24M | $-1.50M | $-3.35M | $21.63M | $-25.45M | $-686.00K | $-673.00K | $-2.55M | $- | $- | $- | $- | $- |
| Inventory | $2.32M | $6.18M | $-7.58M | $3.84M | $-5.54M | $-1.62M | $-533.00K | $-1.83M | $-6.98M | $5.29M | $-6.69M | $-9.55M | $1.93M | $775.00K | $-6.38M | $- | $- | $- | $- | $- |
| Accounts Payables | $-6.28M | $911.00K | $1.73M | $-2.66M | $7.23M | $364.00K | $-743.00K | $-6.51M | $6.43M | $-1.05M | $-861.00K | $1.51M | $250.00K | $-2.54M | $3.58M | $72.00K | $-3.27M | $1.52M | $-2.03M | $-1.20M |
| Other Working Capital | $41.34M | $2.95M | $397.00K | $2.12M | $12.57M | $-9.33M | $12.54M | $3.36M | $-21.91M | $15.74M | $-10.10M | $14.27M | $8.26M | $-3.10M | $-8.02M | $839.00K | $7.87M | $1.60M | $-798.00K | $-8.02M |
| Other Non Cash Items | $1.59M | $267.00K | $19.15M | $2.76M | $749.00K | $2.15M | $-383.00K | $-45.00K | $595.00K | $642.00K | $856.00K | $899.00K | $886.00K | $702.00K | $793.00K | $1.00M | $1.00M | $232.00K | $218.00K | $72.00K |
| Net Cash Provided by Operating Activities | $18.77M | $-2.24M | $5.17M | $3.99M | $4.33M | $16.99M | $-3.74M | $-4.27M | $-11.58M | $62.05M | $-7.82M | $-36.85M | $-18.88M | $-28.51M | $-38.78M | $-40.12M | $-41.19M | $-34.32M | $-29.22M | $-31.80M |
| Investments in Property Plant and Equipment | $-193.00K | $- | $- | $-84.00K | $-56.00K | $-16.00K | $-34.00K | $-24.00K | $32.00K | $-22.00K | $-115.00K | $- | $-251.00K | $-51.00K | $-59.00K | $-20.05M | $-55.00K | $-5.00K | $- | $-223.00K |
| Acquisitions Net | $- | $-25.00K | $25.00K | $- | $14.84M | $12.26M | $-35.57M | $37.90M | $10.00K | $-10.00K | $91.00K | $- | $20.00M | $- | $- | $20.00M | $- | $- | $- | $- |
| Purchases of Investments | $-21.99M | $-54.48M | $-89.26M | $-36.28M | $-60.82M | $-53.09M | $-38.13M | $-52.90M | $-62.80M | $-17.33M | $-25.51M | $-30.22M | $-59.79M | $- | $-23.10M | $-74.36M | $-86.05M | $-210.21M | $-107.77M | $-26.19M |
| Sales Maturities of Investments | $87.48M | $48.13M | $42.44M | $61.88M | $45.98M | $40.83M | $73.70M | $15.00M | $20.10M | $36.40M | $63.80M | $7.50M | $10.00M | $47.90M | $109.15M | $139.25M | $154.75M | $60.55M | $76.55M | $115.20M |
| Other Investing Activities | $- | $25.00K | $-46.80M | $25.61M | $-14.84M | $-12.26M | $35.57M | $-37.90M | $-42.69M | $19.06M | $38.38M | $-22.72M | $-20.00M | $47.90M | $86.05M | $-20.00M | $68.70M | $-149.66M | $-31.22M | $89.01M |
| Net Cash Used for Investing Activities | $65.29M | $-6.35M | $-46.80M | $25.52M | $-14.89M | $-12.28M | $35.53M | $-37.92M | $-42.66M | $19.04M | $38.27M | $-22.72M | $-50.04M | $47.85M | $85.99M | $44.83M | $68.64M | $-149.66M | $-31.22M | $88.79M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $1.29M | $- | $- | $- | $1.21M | $2.68M | $887.00K | $1.11M | $-221.67M | $146.47M | $75.19M | $- |
| Common Stock Repurchased | $-578.00K | $-2.71M | $-1.31M | $-381.00K | $-262.00K | $-1.10M | $-419.00K | $-420.00K | $-100.00K | $-208.00K | $-24.00K | $-569.00K | $5.88M | $- | $- | $- | $6.55M | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $2.72M | $9.40M | $1.14M | $3.99M | $957.00K | $1.66M | $577.00K | $510.00K | $- | $569.00K | $566.00K | $992.00K | $1.21M | $-1.99M | $887.00K | $1.11M | $712.00K | $-76.00K | $2.37M | $2.41M |
| Net Cash Used Provided by Financing Activities | $2.14M | $6.69M | $-178.00K | $3.61M | $695.00K | $552.00K | $158.00K | $90.00K | $1.19M | $361.00K | $542.00K | $423.00K | $1.21M | $2.68M | $887.00K | $1.11M | $712.00K | $146.40M | $77.56M | $2.41M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $86.20M | $-1.90M | $-41.81M | $33.12M | $-9.87M | $5.26M | $31.95M | $-42.10M | $-53.05M | $81.45M | $30.98M | $-59.15M | $-67.71M | $22.02M | $48.10M | $5.82M | $28.16M | $-37.58M | $17.12M | $59.41M |
| Cash at End of Period | $183.58M | $97.38M | $99.27M | $141.08M | $107.95M | $117.83M | $112.57M | $80.62M | $122.72M | $175.76M | $94.31M | $63.32M | $122.47M | $190.18M | $168.16M | $120.07M | $114.25M | $86.08M | $123.67M | $106.55M |
| Cash at Beginning of Period | $97.38M | $99.27M | $141.08M | $107.95M | $117.83M | $112.57M | $80.62M | $122.72M | $175.76M | $94.31M | $63.32M | $122.47M | $190.18M | $168.16M | $120.07M | $114.25M | $86.08M | $123.67M | $106.55M | $47.14M |
| Operating Cash Flow | $18.77M | $-2.24M | $5.17M | $3.99M | $4.33M | $16.99M | $-3.74M | $-4.27M | $-11.58M | $62.05M | $-7.82M | $-36.85M | $-18.88M | $-28.51M | $-38.78M | $-40.12M | $-41.19M | $-34.32M | $-29.22M | $-31.80M |
| Capital Expenditure | $-193.00K | $- | $- | $-84.00K | $-56.00K | $-16.00K | $-34.00K | $-24.00K | $32.00K | $-22.00K | $-115.00K | $- | $-251.00K | $-51.00K | $-59.00K | $-20.05M | $-55.00K | $-5.00K | $- | $-223.00K |
| Free Cash Flow | $18.58M | $-2.24M | $5.17M | $3.90M | $4.27M | $16.97M | $-3.78M | $-4.29M | $-11.54M | $62.03M | $-7.94M | $-36.85M | $-19.14M | $-28.56M | $-38.84M | $-60.18M | $-41.25M | $-34.33M | $-29.22M | $-32.02M |
Kiniksa Pharmaceuticals Dividends
Explore Kiniksa Pharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
Kiniksa Pharmaceuticals News
Read the latest news about Kiniksa Pharmaceuticals, including recent articles, headlines, and updates.
How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6%
The average of price targets set by Wall Street analysts indicates a potential upside of 58.6% in Kiniksa Pharmaceuticals (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?
Kiniksa Pharmaceuticals (KNSA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High?
The consensus price target hints at a 73.4% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively – – ARCALYST 2025 net product revenue expected to be $560 - $580 million – – KPL-387 Phase 2/3 clinical trial in recurrent pericarditis expected to initiate in mid-2025; Phase 2 data expected in 2H 2026 – – Abiprubart development in Sjögren's Disease to be discontinued – – Current operating plan expected to remain cash flow positive on an annual basis – – Conference call and webcast scheduled for 8:30 am ET today –
Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy
– Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 – – KPL-387 Phase 1 single ascending dose data support potential monthly dosing – – Kiniksa continues to focus development on diseases with unmet need, prioritizing cardiovascular indications – – Kiniksa to discontinue abiprubart development in Sjögren's Disease – LONDON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today announced the development program for KPL-387 in recurrent pericarditis and provided an update on its corporate strategy. KPL-387 is an independently developed monoclonal antibody that binds human interleukin-1 receptor 1 (IL-1R1), inhibiting the signaling activity of the cytokines interleukin-1α (IL-1α) and interleukin-1β (IL-1β).
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 25, 2025 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2024 financial results and recent portfolio execution.
Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance
– ARCALYST ® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth – – ARCALYST 2025 net product revenue expected to be $560 - $580 million – – Kiniksa expects to remain cash flow positive on an annual basis –
Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
LONDON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference
LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024 at 9:35 a.m. Eastern Time.
Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference
LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 12:00 p.m. Greenwich Mean Time (7:00 a.m. Eastern Time).
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2024 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chairman and Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Liisa Bayko - Evercore ISI Paul Choi - Goldman Sachs Eva Fortea-Verdejo - Wells Fargo David Nierengarten - Wedbush Securities Anupam Rama - JPMorgan Operator Good day and thank you for standing by. Welcome to Kiniksa Pharmaceuticals Third Quarter 2024 Earnings Conference Call.
Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $410 - $420 million – – Life DisRPted ™ disease awareness campaign for recurrent pericarditis launched in partnership with NHL Hall of Famer, Henrik Lundqvist, and GRAMMY ® Award-winning singer-songwriter, Carly Pearce – – Kiniksa expects to remain cash flow positive on an annual basis – – Conference call and webcast scheduled for 8:30 am ET today –
Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024
LONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 29, 2024 at 8:30 a.m. Eastern Time to report its third quarter 2024 financial results and recent portfolio execution.
What Makes Kiniksa Pharmaceuticals (KNSA) a Good Fit for 'Trend Investing'
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Wall Street Analysts Think Kiniksa Pharmaceuticals (KNSA) Could Surge 42.34%: Read This Before Placing a Bet
The consensus price target hints at a 42.3% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Kiniksa Pharmaceuticals (KNSA) is on the Move, Here's Why the Trend Could be Sustainable
Kiniksa Pharmaceuticals (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference
LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 at 8:00 a.m. Eastern Time.
Wall Street Analysts Believe Kiniksa Pharmaceuticals (KNSA) Could Rally 30.11%: Here's is How to Trade
The consensus price target hints at a 30.1% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat
Kiniksa Pharmaceuticals surged after the company reported strong second quarter results and increased the full year net sales guidance range for Arcalyst. The strong performance is driven by increased demand following the recent sales force expansion. The improved outlook for Arcalyst warrants an increase in the valuation range.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for KNSA.